WLF v. Crawford? Off-Label Dissemination Dissent May Trigger Second Suit
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent request for comments on labeling and promotional speech regulation, while an "encouraging sign," may be an attempt to stave off further litigation, Washington Legal Foundation Chief Counsel Richard Samp asserted May 30
You may also be interested in...
FDA Opens Floor For Debate Of Off-Label Claims, First Amendment Issues
FDA's request for comments on First Amendment issues creates a forum for stakeholders to submit comments on FDA's policy regarding off-label claims
FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”